PubRank

Bernard A Fox

Author PubWeight™ 69.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014 3.21
2 Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012 2.88
3 The immune score as a new possible approach for the classification of cancer. J Transl Med 2012 2.79
4 Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011 2.44
5 Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002 1.89
6 A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med 2008 1.77
7 Cancer and inflammation: promise for biologic therapy. J Immunother 2010 1.72
8 Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood 2007 1.52
9 Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 2003 1.50
10 Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 2005 1.36
11 The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 2013 1.31
12 Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009 1.31
13 Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 2011 1.30
14 Signaling through OX40 enhances antitumor immunity. Semin Oncol 2010 1.27
15 Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res 2011 1.24
16 Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther 2003 1.17
17 Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003 1.17
18 Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 2009 1.11
19 Supporting the advancement of science: open access publishing and the role of mandates. J Transl Med 2012 1.10
20 Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy 2009 1.10
21 gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res 2004 1.08
22 Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 2013 1.04
23 Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med 2011 1.02
24 Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 2006 1.02
25 SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011 1.02
26 Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J Immunol 2009 1.02
27 Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res 2008 1.02
28 TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol 2003 1.00
29 Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 2011 0.99
30 Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. J Immunol 2012 0.97
31 Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med 2013 0.95
32 Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology 2012 0.94
33 Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res 2014 0.93
34 Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med 2009 0.91
35 Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J Immunother 2007 0.91
36 CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. J Immunol 2002 0.91
37 Announcing the tumor immunology and biological cancer therapy section (edited by iSBTc) of the Journal of Translational Medicine. J Transl Med 2009 0.91
38 Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother 2003 0.89
39 Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells. J Immunol 2003 0.89
40 Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol 2009 0.89
41 Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012 0.87
42 Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother 2002 0.86
43 Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med 2007 0.85
44 Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. Immunology 2003 0.85
45 Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells. J Transl Med 2014 0.83
46 Multiple vaccinations: friend or foe. Cancer J 2011 0.83
47 Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist 2010 0.82
48 Immunotherapy of lung cancer: an update. Onkologie 2006 0.81
49 Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines. J Transl Med 2007 0.81
50 Immunoprofiling for prognostic assessment of colon cancer: a novel complement to ultrastaging. J Gastrointest Surg 2015 0.81
51 Allogeneic breast cancer cell vaccines. Clin Breast Cancer 2003 0.81
52 Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep 2005 0.81
53 Future of cancer vaccines. Methods Mol Biol 2014 0.81
54 [Mechanism of augmented anti-tumor immunity in reconstituted lymphopenic mice immunized with melanoma vaccine]. Zhonghua Zhong Liu Za Zhi 2005 0.79
55 Lean oncology: a new model for oncologists. J Transl Med 2012 0.79
56 Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor. J Transl Med 2007 0.79
57 Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Cell Immunol 2004 0.78
58 Biocompatibility of a xenogenic elastin-based biomaterial in a murine implantation model: the role of aluminum chloride pretreatment. J Biomed Mater Res A 2004 0.78
59 Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells. Clin Exp Metastasis 2004 0.78
60 The promising future of proteomics in cancer diagnosis and treatment. Eur J Gastroenterol Hepatol 2005 0.77
61 Current immunotherapeutic strategies in lung cancer. Surg Oncol Clin N Am 2007 0.75
62 [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine]. Zhonghua Zhong Liu Za Zhi 2005 0.75
63 Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes. J Immunother 2003 0.75
64 Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation. J Immunother 2017 0.75
65 Characterization of immune responses in gastric cancer patients: a possible impact of H. pylori to polarize a tumor-specific type 1 response? Clin Immunol 2006 0.75
66 Targeting and amplification of immune killing of tumor cells by pro-Smac. Int J Cancer 2004 0.75
67 Adoptive cellular immunotherapy of cancer: a three-signal paradigm for translating recent developments into improved treatment strategies. Cancer Treat Res 2005 0.75
68 Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein. J Immunother 2008 0.75
69 Correction: Multispectral Imaging of T and B Cells in Murine Spleen and Tumor. J Immunol 2017 0.75